| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Affiliations of authors: Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA (BF, DLW, NW); Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh, Pittsburgh, PA (JPC, RSC, WMC); Hotel-Dieu de Montreal, Montreal, Quebec, Canada (AR); University of Texas M. D. Anderson Cancer Center, Houston, TX (TBB); Boston Medical Center, Boston, MA (MTK); Southeast Cancer Control Consortium, Winston-Salem, NC (JNA); Jewish General Hospital, Montreal, Quebec, Canada (RGM); Neag Comprehensive Cancer Center, University of Connecticut, Farmington, CT (CDR); Fox Chase Cancer Center, Philadelphia, PA (JMJ); National Cancer Institute, Bethesda, MD (LGF); Allegheny General Hospital, Pittsburgh, PA (NW)
Correspondence to: Bernard Fisher, MD, University of Pittsburgh/Department of Surgery, Magee-Womens Hospital, 300 Halket Street, Suite 350, Pittsburgh, PA 15213-3180 (e-mail: fisherb2{at}upmc.edu).
Background: Initial findings from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (P-1) demonstrated that tamoxifen reduced the risk of estrogen receptor–positive tumors and osteoporotic fractures in women at increased risk for breast cancer. Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings. Methods: Women (n = 13 388) were randomly assigned to receive placebo or tamoxifen for 5 years. Rates of breast cancer and other events were compared by the use of risk ratios (RRs) and 95% confidence intervals (CIs). Estimates of the net benefit from 5 years of tamoxifen therapy were compared by age, race, and categories of predicted breast cancer risk. Statistical tests were two-sided. Results: After 7 years of follow-up, the cumulative rate of invasive breast cancer was reduced from 42.5 per 1000 women in the placebo group to 24.8 per 1000 women in the tamoxifen group (RR = 0.57, 95% CI = 0.46 to 0.70) and the cumulative rate of noninvasive breast cancer was reduced from 15.8 per 1000 women in the placebo group to 10.2 per 1000 women in the tamoxifen group (RR = 0.63, 95% CI = 0.45 to 0.89). These reductions were similar to those seen in the initial report. Tamoxifen led to a 32% reduction in osteoporotic fractures (RR = 0.68, 95% CI = 0.51 to 0.92). Relative risks of stroke, deep-vein thrombosis, and cataracts (which increased with tamoxifen) and of ischemic heart disease and death (which were not changed with tamoxifen) were also similar to those initially reported. Risks of pulmonary embolism were approximately 11% lower than in the original report, and risks of endometrial cancer were about 29% higher, but these differences were not statistically significant. The net benefit achieved with tamoxifen varied according to age, race, and level of breast cancer risk. Conclusions: Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer. Readily identifiable subsets of individuals comprising 2.5 million women could derive a net benefit from the drug.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
- Jack Cuzick, John F. Forbes, and Anthony Howell
J Natl Cancer Inst 2006 98: 643.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  V. C. Jordan The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death? J. Clin. Oncol., June 20, 2008; 26(18): 3073 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Rise of Raloxifene and the Fall of Invasive Breast Cancer J Natl Cancer Inst, June 18, 2008; 100(12): 831 - 833. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jayachandran and S. J. Freedland Prevention of Prostate Cancer: What We Know and Where We Are Going American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Weng, Y. Kashida, S. K. Kulp, D. Wang, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor Mol. Cancer Ther., April 1, 2008; 7(4): 800 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Eastell, J. E. Adams, R. E. Coleman, A. Howell, R. A. Hannon, J. Cuzick, J. R. Mackey, M. W. Beckmann, and G. Clack Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 J. Clin. Oncol., March 1, 2008; 26(7): 1051 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Parton and I. E. Smith Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 745 - 752. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Kahn Moving Research From Bench to Bedside to Community: There Is Still More to Do J. Clin. Oncol., February 1, 2008; 26(4): 523 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hardman, E. Emmerson, L. Campbell, and G. S. Ashcroft Selective Estrogen Receptor Modulators Accelerate Cutaneous Wound Healing in Ovariectomized Female Mice Endocrinology, February 1, 2008; 149(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bertelsen, L. Bernstein, J. H. Olsen, L. Mellemkjaer, R. W. Haile, C. F. Lynch, K. E. Malone, H. Anton-Culver, J. Christensen, B. Langholz, et al. Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study J Natl Cancer Inst, January 2, 2008; 100(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fatouros, G. Baltoyiannis, and D. H. Roukos The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and B. W. O'Malley Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer J. Clin. Oncol., December 20, 2007; 25(36): 5815 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Willey and C. Cocilovo Screening and Follow-up of the Patient at High Risk for Breast Cancer Obstet. Gynecol., December 1, 2007; 110(6): 1404 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Estrogen Receptors in BRCA1-Mutant Breast Cancer: Now You See Them, Now You Don't J Natl Cancer Inst, November 21, 2007; 99(22): 1655 - 1657. [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2207 - 2209. [Full Text] [PDF]
|
|
|
|
|
|
C. Fabian Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2210 - 2212. [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Horn, K. E. O. Torres, J. M. Naylor, M. J. Cwik, C. J. Detrisac, I. M. Kapetanovic, R. A. Lubet, J. A. Crowell, and D. L. McCormick Subchronic Toxicity and Toxicogenomic Evaluation of Tamoxifen Citrate + Bexarotene in Female Rats Toxicol. Sci., October 1, 2007; 99(2): 612 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chu, A. Fyles, E. M. Sellers, D. R. McCready, J. Murphy, T. Pal, and S. A. Narod Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use Carcinogenesis, October 1, 2007; 28(10): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoque, H. L. Parnes, M. E. Stefanek, J. V. Heymach, P. H. Brown, and S. M. Lippman Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research Cancer Res., October 1, 2007; 67(19): 8989 - 8993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al. Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. MOODY Thymosin {alpha}1 as a Chemopreventive Agent in Lung and Breast Cancer Ann. N.Y. Acad. Sci., September 1, 2007; 1112(1): 297 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Robson and K. Offit Management of an Inherited Predisposition to Breast Cancer N. Engl. J. Med., July 12, 2007; 357(2): 154 - 162. [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Pinsky, M. Rebner, L. J. Pierce, M. A. Ben-David, F. Vicini, K. A. Hunt, and M. A. Helvie Recurrent Cancer After Breast-Conserving Surgery with Radiation Therapy for Ductal Carcinoma in Situ: Mammographic Features, Method of Detection, and Stage of Recurrence Am. J. Roentgenol., July 1, 2007; 189(1): 140 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J Santen, N. F Boyd, R. T Chlebowski, S. Cummings, J. Cuzick, M. Dowsett, D. Easton, J. F Forbes, T. Key, S. E Hankinson, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model Endocr. Relat. Cancer, June 1, 2007; 14(2): 169 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van den Berg, H. van Tinteren, N. van Zandwijk, C. Visser, A. Pasic, C. Kooi, T. G. Sutedja, P. Baas, K. Grunberg, W. J. Mooi, et al. The Influence of Fluticasone Inhalation on Markers of Carcinogenesis in Bronchial Epithelium Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 1061 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, N. Rotmensz, B. Bonanni, P. Boyle, G. Viale, A. Costa, V. Sacchini, R. Travaglini, G. D'Aiuto, et al. Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy J Natl Cancer Inst, May 2, 2007; 99(9): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan SERMs: Meeting the Promise of Multifunctional Medicines J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Dallal, J. Sullivan-Halley, R. K. Ross, Y. Wang, D. Deapen, P. L. Horn-Ross, P. Reynolds, D. O. Stram, C. A. Clarke, H. Anton-Culver, et al. Long-term Recreational Physical Activity and Risk of Invasive and In Situ Breast Cancer: The California Teachers Study Arch Intern Med, February 26, 2007; 167(4): 408 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Veronesi, P. Maisonneuve, and A. Decensi Tamoxifen: An Enduring Star J Natl Cancer Inst, February 21, 2007; 99(4): 258 - 260. [Full Text] [PDF]
|
|
|
|
|
|
J. Cuzick, J. F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial J Natl Cancer Inst, February 21, 2007; 99(4): 272 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Powles, S. Ashley, A. Tidy, I. E. Smith, and M. Dowsett Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial J Natl Cancer Inst, February 21, 2007; 99(4): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Armstrong, D. A. Quistberg, E. Micco, S. Domchek, and C. Guerra Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med, November 13, 2006; 166(20): 2260 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G VOGEL Recent Results from Clinical Trials Using SERMs to Reduce the Risk of Breast Cancer Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 127 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Lacey Jr, M. H. Greene, S. S. Buys, D. Reding, T. L. Riley, C. D. Berg, R. M. Fagerstrom, and P. Hartge Ovarian Cancer Screening in Women With a Family History of Breast or Ovarian Cancer. Obstet. Gynecol., November 1, 2006; 108(5): 1176 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice Clin. Cancer Res., September 1, 2006; 12(17): 5010 - 5013. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Gradishar and D. Cella Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer JAMA, June 21, 2006; 295(23): 2784 - 2786. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. McCloskey Aromatase Inhibitors and Bone Health IBMS BoneKEy, June 1, 2006; 3(6): 5 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cuzick, J. F. Forbes, and A. Howell Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, May 3, 2006; 98(9): 643 - 643. [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher and J. P. Costantino RESPONSE: Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst, May 3, 2006; 98(9): 643 - 644. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Beattie, J. P. Costantino, S. R. Cummings, D. L. Wickerham, V. G. Vogel, M. Dowsett, E. J. Folkerd, W. C. Willett, N. Wolmark, and S. E. Hankinson Endogenous Sex Hormones, Breast Cancer Risk, and Tamoxifen Response: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1) J Natl Cancer Inst, January 18, 2006; 98(2): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Tamoxifen for Breast Cancer Prevention: Extended Follow-Up Journal Watch (General), December 20, 2005; 2005(1220): 5 - 5. [Full Text]
|
|